5-Ethylpyridin-2-carbonsaeureethylester | 13509-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Ethylpyridin-2-carbonsaeureethylester
• 英文别名: ethyl 5-ethylpyridine-2-carboxylate；5-ethyl-pyridine-2-carboxylic acid ethyl ester；5-Aethyl-pyridin-2-carbonsaeure-aethylester
• CAS: 13509-15-4
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: MOCKUVGMROUXCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Ethylpyridin-2-carbonsaeureethylester 在 ammonium hydroxide 、 三氯氧磷 作用下， 生成 5-乙基吡啶-2-甲腈
  参考文献：
  名称：

  153.育亨宾和相关生物碱的组成。第九部分 合成2-（4：5-二乙基-2-吡啶基）-3-乙基吲哚（丁烯丙基或丙烯胺）和两种相关化合物

  摘要：

  DOI：

  10.1039/jr9560000771
• 作为产物：
  描述：

  5-溴-2-吡啶羧酸 在 四(三苯基膦)钯 、 palladium 10% on activated carbon 硫酸 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 5-Ethylpyridin-2-carbonsaeureethylester
  参考文献：
  名称：

  FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

  摘要：

  公开号：

  EP2471789B9

文献信息

• PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM
  申请人：Biome Bioplastics Limited

  公开号：US20180148752A1

  公开（公告）日：2018-05-31

  The present invention relates to processes for the formation of pyridinedicarboxylic acid (PDCA), in particular, 2,4-pyridinedicarboxylic acid (2,4-PDCA) and 2,5-pyridinedicarboxylic acid (2,5-PDCA), and mono- and diester derivatives thereof, from 3,4-dihydroxybenzoic acid, via a biocatalytic reaction using, for example, a protocatechuate dioxygenase such as protocatechuate 4,5-dioxygenase or protocatechuate 2,3-dioxygenase, and a nitrogen source. The invention also relates to copolymers that comprise the pyridinedicarboxylic acid monomers and derivatives thereof, processes for the formation of the copolymers and uses for the copolymers.

  本发明涉及从3,4-二羟基苯甲酸通过生物催化反应，使用原儿茶酸双氧酶例如原儿茶酸4,5-双氧酶或原儿茶酸2,3-双氧酶和氮源等，形成吡啶二甲酸（PDCA），特别是2,4-吡啶二甲酸（2,4-PDCA）和2,5-吡啶二甲酸（2,5-PDCA）及其单酯和双酯衍生物的过程。本发明还涉及包含吡啶二甲酸单体及其衍生物的共聚物，形成共聚物的过程以及共聚物的用途。
• SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20160108052A1

  公开（公告）日：2016-04-21

  The following compound is provided as an agent for treating a disease induced by production, secretion and/or deposition of amyloid β protein, for example, a compound represented by the formula (I): wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group, R 1 is optionally substituted lower alkyl or the like, R 2a and R 2b are each independently hydrogen, optionally substituted lower alkyl or the like, R 3a and R 3c are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

  以下化合物作为治疗由淀粉样β蛋白的产生、分泌和/或沉积引起的疾病的药剂，例如由式(I)表示的化合物：其中环A是可选取代的碳环基或可选取代的杂环基，R1是可选取代的低碳基或类似物，R2a和R2b各自独立地是氢、可选取代的低碳基或类似物，R3a和R3b各自独立地是氢、卤素、羟基、可选取代的低碳基或类似物，或其药学上可接受的盐或溶剂。
• Libermann et al., Bulletin de la Societe Chimique de France, 1958, p. 687,691
  作者：Libermann et al.

  DOI：——

  日期：——
• Synthesis and evaluation of hedgehog signaling inhibitor with novel core system
  作者：Tomohiro Ohashi、Yuta Tanaka、Zenyu Shiokawa、Hiroshi Banno、Toshio Tanaka、Sachio Shibata、Yoshihiko Satoh、Hiroko Yamakawa、Yukiko Yamamoto、Harumi Hattori、Shigeru Kondo、Maki Miyamoto、Hideaki Tojo、Atsuo Baba、Satoshi Sasaki

  DOI：10.1016/j.bmc.2015.05.036

  日期：2015.8

  As we previously reported, N-methylpyrrolo[3,2-c] pyridine derivatives 1 (TAK-441) was discovered as a clinical candidate of hedgehog (Hh) signaling inhibitor by modification of the upper part. We next focused on modification of the lower part including core skeletons to discover new Hh signaling inhibitors with novel core rings. Efforts to find novel chemotypes by using X-ray single crystal structure analysis led to some potent Hh signaling inhibitors (2c, 2d, 2e, 2f) with novel core ring systems, which had benzamide moiety at the 5-position as a key component for potent activity. The suppression of Gli1 expression with these new Hh signaling inhibitors were weaker than that of compound 1 (TAK-441) because of low pharmacokinetic property. We recognized again TAK-441 is a good compound as clinical candidate with good structural and pharmacokinetic advantages. (C) 2015 Elsevier Ltd. All rights reserved.
• A directed metalation route to the zwitterionic indole alkaloids. Syntheses of indolo[2,3-a]quinolizine, flavopereirine, flavocarpine, and dihydroflavopereirine
  作者：Gordon W. Gribble、David A. Johnson

  DOI：10.1016/s0040-4039(00)96702-9

  日期：——